Novartis (NVS)

[DewDiligence]

FDA approves NVS’ Kymriah (CTL019 CAR-T) for pediatric ALL:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm

[biotech_researcher]

New drug from Novartis helps prevent heart attacks by curbing inflammation

For the first time, a drug has helped prevent heart attacks by curbing inflammation, a new and very different approach than lowering cholesterol, the focus for many years.

Read more: https://www.cnbc.com/2017/08/27/a-first-drug-lowers-heart-risks-by-curbing-inflammation.html

[Inoviorulez]

https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-must

[malt66]

Sell short this crap along with other big pharma...


Why...?

Either they reprice, face a major collapse in US GDP, or Trump can use executive order violations of 15 USC Chapter 1

https://market-ticker.org/akcs-www?post=232235

[DewDiligence]

NVS 2Q17 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q2-2017-ir-presentation.pdf

[Inoviorulez]

https://seekingalpha.com/article/4087475-novartis-wins-fda-panel-backing-new-car-t-therapy-treatment

[DewDiligence]

NVS’ own PR on CTL019 ODAC panel:

https://www.sec.gov/Archives/edgar/data/1114448/000117184317004057/f6k_071217.htm

[DewDiligence]

FDA approves Tafinlar+Mekinist for BRAF-V600E NSCLC: #msg-132422635.

[DewDiligence]

Ilaris reduces MACE in secondary-prevention setting: #msg-132398529.

[DewDiligence]

RTH258 non-inferior to Eylea with less-frequent injections: #msg-132328161.

[DewDiligence]

EU approves NVS’ Rituxan FoB, called Rixathon:

https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathonr-biosimilar-rituximab-treat-blood

This is the second Rituxan FoB in Europe; Celltrion's Truxima was the first.

[DewDiligence]

NVS “Meet the Management” Investor Day slides:

#msg-131777804

[DewDiligence]

CHMP approves Zykadia in first-line ALK+ NSCLC:

https://finance.yahoo.com/news/chmp-backs-novartiss-zykadia-first-123844663.html

In the US, the PDUFA date for this indication is 8/22/17.

[PStockPickz]

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

[DewDiligence]

NVS 1Q17 CC slides:

https://www.novartis.com/sites/www.novartis.com/files/q1-2017-ir-presentation.pdf

[DewDiligence]

NVS could take $15-25B loss on Alcon sale:

https://www.bloomberg.com/gadfly/articles/2017-04-20/novartis-alcon-sale-will-take-a-bargain-price

[DewDiligence]

NVS, AGN collaborate on phase-2b for NASH combo: #msg-130568056.

[DewDiligence]

NVS licenses dry-eye drug candidate from (private) Lubris, LLC: #msg-130284224.

[DewDiligence]

Serelaxin fails revamped phase-3 trial in acute HF: #msg-129752197.

[DewDiligence]

FDA approves NVS’ Kisqali (f/k/a LEE011) for first-line HR+/HER2- breast cancer:

https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-lee011-receives-fda-approval-first-line-treatment

The main competitor for Kisqali is PFE’s Ibrance.

[trendmkr]

Novartis AG (ADR) (NYSE:NVS) Fined And Some Products To Be Temporarily Suspended In South Korea https://marketexclusive.com/novartis-ag-adr-nysenvs-fined-products-temporarily-suspended-south-korea/78526/?icd1

[trendmkr]

Novartis AG (NYSE:NVS) Greater Use Of Technology In Transforming Medical Education https://marketexclusive.com/glaxosmithkline-plc-nysegsks-two-drug-cocktail-aim-reduce-number-pills-hiv-patients-take-daily/72033/?icd1

[DewDiligence]

Some info about NVS’ RTH258 for AMD: #msg-128240149.

[DewDiligence]

NVS CC slides…

4Q16 results:
https://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation.pdf

Pipeline development:
https://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation-development.pdf

Pipeline research:
https://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation-research.pdf

[DewDiligence]

NVS inks two deals…

CNAT: #msg-127298914
Encore Vision: #msg-127306395

[Ecomike]

Down nearly 4% in one day on good earnings news. Why?

[DewDiligence]

NVS 3Q16 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q3-2016-ir-presentation.pdf

[DewDiligence]

NVS’ LEE011 data impress in first-line HR+/HER2- breast cancer:

#msg-125671020

[DewDiligence]

NVS presents phase-3 data in SPMS:

https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study?hootPostID=cfa242079cd3be03006662ed67970b9c

NVS announced three weeks ago that this trial hit its primary endpoint (#msg-124762084).

[DewDiligence]

NVS reduces MNTA stake via 10b5-1 plan: #msg-124870976.

[DewDiligence]

What will NVS do about AMGN's Enbrel patent that runs until 2028?

[DewDiligence]

FDA approves NVS’ Enbrel FoB, but... #msg-124870707.

[DewDiligence]

NVS hits phase-3 primary endpoint in SPMS:

https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients

Novartis today announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, compared with placebo. The EXPAND study represents the largest randomized, controlled study in SPMS to date.

[venturecapp]

Novartis AG Licenses LGT209 To Cyon Therapeutics, Teams Up With KRCS http://marketexclusive.com/novartis-ag-nysenvs-licenses-lgt209-cyon-therapeutics-inc-teams-krcs/24842/?icd1

[DewDiligence]

NVS’ recent-launch successes—Cosentyx yes, Entresto no:

http://www.bloomberg.com/news/articles/2016-07-19/novartis-profit-declines-as-competition-hurts-cancer-drug-sales

[DewDiligence]

FDA rejects NVS' Enbrel FoB: #msg-123963130.

[DewDiligence]

NVS 2Q16 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q2-2016-ir-presentation.pdf

[Fibanotch]

will be 90 by next year

[venturecapp]

Novartis, Eisai To Cooperate In Cancer Drugs Marketing In The U.S.
http://marketexclusive.com/novartis-ag-nysenvs-eisai-co-ltd-otcmktsesaly-cooperate-cancer-drugs-marketing-u-s/7648/?icd1

[DewDiligence]

NVS to run 40+ Entresto trials to boost sales:

http://finance.yahoo.com/news/novartis-launches-entresto-trials-bid-142012772.html

[stocktrademan]

$NVS recent news/filings

bearish 72.68

## source: finance.yahoo.com

$NVS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NVS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NVS/company-info
Ticker: $NVS
OTC Market Place: Not Available
CIK code: 0001114448
Company name: Novartis AG
Company website: http://www.novartis.com
Incorporated In: Switzerland

Business Description:

$NVS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$NVS extra dd links

Company name: Novartis AG
Company website: http://www.novartis.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NVS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NVS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NVS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NVS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NVS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/news - http://finance.yahoo.com/q/h?s=NVS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NVS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NVS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NVS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NVS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NVS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NVS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Novartis+AG&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Novartis+AG
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Novartis+AG&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.novartis.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.novartis.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.novartis.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NVS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NVS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NVS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NVS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NVS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001114448&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NVS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NVS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NVS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NVS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NVS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NVS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NVS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NVS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NVS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NVS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NVS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NVS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NVS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NVS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NVS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NVS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NVS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NVS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NVS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NVS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NVS



$NVS DD Notes ~ http://www.ddnotesmaker.com/NVS

[DewDiligence]

Entresto is off to a slow start: #msg-121250538.

[Penny Machine]

Looks like Offices are being Raided over Bribery Concerns
http://www.statnews.com/pharmalot/2016/02/22/novartis-south-korea-bribes-doctors/

[DewDiligence]

The 20-F annual report has been filed:

http://www.sec.gov/Archives/edgar/data/1114448/000104746916009872/a2227040z20-f.htm

[DewDiligence]

NVS 4Q15 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q4-2015-ir-presentation.pdf

[DewDiligence]

Alcon has become a serious drag on NVS: #msg-119762239.

[DewDiligence]

Entresto might increase risk of AMD and AD, say journal authors:

#msg-119077406

[venturecapp]

Novartis Reaffirms its CAR T Dominance

http://marketexclusive.com/novartis-reaffirms-its-car-t-dominance/1139/

[DewDiligence]

FDA approves generic Gleevec from Sun Pharma: #msg-118939751.

[DewDiligence]

FDA reviewing NVS’ 351(k) submission for Neulasta FoB: #msg-118583523.